CN114231480A

CN114231480A - Human lung specific channel cell line

Info

Publication number: CN114231480A
Application number: CN202111531357.9A
Authority: CN
Inventors: 宋东莉; 王向东
Original assignee: Zhongshan Hospital Fudan University
Current assignee: Zhongshan Hospital Fudan University
Priority date: 2021-12-15
Filing date: 2021-12-15
Publication date: 2022-03-25

Abstract

The invention relates to a human lung specific channel cell line, and belongs to the technical field of biological medicines. The invention transfects primary human lung idiosyncratic cell with lentivirus carrying TERT gene and CDK4 gene; and continuously subculturing the identified human lung idiosyncratic cell stably transfected with TERT and CDK4 for more than 50 generations to obtain a stable human lung idiosyncratic cell line. The obtained complex cell can be used for basic research on pathogenesis and intervention of acute and chronic diseases, tumors and the like, and can be used for research on communication and interaction between cells and other cell types; provides a cell model for the clinical new drug screening and the drug treatment mechanism research and reserves the subsequent research.

Description

Human lung specific channel cell line

Technical Field

The invention relates to a human lung specific channel cell line, and belongs to the technical field of biological medicines.

Background

The function of the idiosyncratic cells is researched at present, the idiosyncratic cells primarily extracted from different organs (lung, kidney, heart and the like) of different species of animals (such as mice, rats, pigs and the like) are used, the extraction process is time-consuming, and each extraction needs to be separated, purified and identified, and a large amount of manpower and material resources are required to be invested. Since the isolation and extraction of primary cells are performed by different persons at a plurality of times, it is difficult to ensure the purity and stability of the extracted cells. How to ensure the purity of cells, enable the cells to be passaged for a long time and ensure the stability of the cells (avoid batch difference) is used for clinical application research and basic research, and for research in the fields of stem cell development and differentiation and the like, which becomes a problem to be solved urgently in the technical field.

Disclosure of Invention

The invention aims to solve the technical problem of how to obtain a human lung idiosyncratic cell line and application thereof.

In order to solve the above problems, the technical scheme adopted by the present invention is to provide a human lung specific channel cell line, which is an immortalized specific channel cell line; the cell strain is preserved in China Center for Type Culture Collection (CCTCC) at 11/02/2021, the name of the culture is human lung specific cell line hTC-S1011, and the preservation number is CCTCC NO: C2021275.

the invention provides an application of a human lung specific channel cell line in constructing a disease model.

The invention provides an application of a human lung specific channel cell line in constructing a model for researching intercellular communication and interaction.

The invention provides an application of a human lung specific cell line in constructing a model for clinical new drug screening and drug treatment mechanism research.

The invention provides an application of a human lung specific cell line in preparing a medicament for treating and/or preventing acute lung injury.

The invention provides an application of a human lung specific channel cell line in preparing a medicament for early treatment of acute myocardial infarction.

The invention provides an application of a human lung specific cell line in preparing a medicament for treating chronic refractory wound.

The invention provides an application of a human lung specific cell line in preparing a medicament for cell therapy.

A method for constructing a human lung Trogopterus cell line comprises the following steps:

1. when primary specific channel cells are extracted, a staged adherence method is adopted: collecting waste tissue after operation, and cutting into 1mm in physiological saline under aseptic condition³The tissue block is placed in 2mg/ml collagenase type II for 30 minutes at 37 ℃, filtered by a sieve with 70 micron aperture, centrifuged for 5 minutes at 1500rpm, the supernatant is discarded, the cell sediment is collected, cultured for 30 minutes in DMEM/F12 culture solution containing 10% FBS and 10-40ng/ml EGF and/or FGF, after the fibroblasts are attached to the wall, the supernatant is transferred to another culture dish, the culture solution is changed after 12 hours of culture, and the specific complex cells are observed under a microscope after the culture is continued for 3-5 days.

The culture solution is as follows: DMEM/F12 medium was supplemented with 10% volume fraction FBS, 10-40ng/mL Epidermal Growth Factor (EGF) and/or Fibroblast Growth Factor (FGF), 2mol/L glutamine and 100mg/mL penicillin/streptomycin.

2. Flow cytometry labeling of specific cell-specific markers: CD34⁺PDGFRα⁺vimentin⁺Specific collateral cell: culturing primary human lung Terra cells to 80% cell density, digesting the cells with digestive juice to 80% round, sucking the culture solution with sterile dropper, and blowing to blow the cells to 75 μmCentrifuging at room temperature at 1000rpm for 5min after filtering with a rice pore size filter screen; discarding the centrifuged supernatant, resuspending the cells with a flow-staining buffer and calculating the cell viability; supplementing the buffer solution to 100 microliter volume, adding 5 microliter each of vimentin, CD34 and PDGFR alpha antibody, incubating for 30 minutes at 4 ℃ in the dark, adding 1mL of flow type staining buffer solution, 1000rpm for 5min, and centrifuging at 4 ℃; discard the centrifuged supernatant as 10⁷Cells were supplemented with flow staining buffer at density per mL for flow sorting.

The digestive juice is as follows: Trypsin-EDTA digest containing 0.25% trypsin and 0.02% EDTA.

The flow type staining buffer solution comprises: to an acid buffered saline (PBS) was added 1.5% by volume of Bovine Serum Albumin (Bovine Serum Albumin, BSA).

3. Flow cytometry sorting of CD34⁺PDGFRα⁺vimentin⁺Specific collateral cell: prepare blank control and single dye tubes, set appropriate drop delay, voltage and fluorescence compensation, for CD34⁺PDGFRα⁺vimentin⁺Setting a door for cells, adding 2mL of sterile culture solution into a sterile 15mL centrifuge tube, placing in a collecting tank, and performing flow sorting.

4. Identification based on morphology and immunolabeling: after sorting, observation of the specific structure telopode and immunolabeling were performed to identify the idiosyncratic cells. Positive expression of vimentin and CD34 was observed under confocal microscopy. After staining the immune colloidal gold particles, the expression of the specific network cells vimentin, CD34 and/or PDGFR alpha is observed to be positive under an electron microscope.

5. Constructing an immortalized human lung idiosyncratic cell line:

5.1 packaging of lentiviruses carrying the TERT Gene: inoculating 293T cells into 10% FBS non-resistant DMEM culture solution at 37 deg.C and 5% CO₂Culturing for 24h in an incubator, and adding the transfection complex dropwise when the cell density reaches 50%; culturing for 16h, sucking out original culture medium, replacing with 10% volume fraction FBS, 0.01mol/L cholesterol, 0.01mol/L egg yolk lecithin and chemically defined concentrated Advanced DMEM virus packaging solution, culturing for 48h, and collecting cell supernatant to obtain the final productTo a lentivirus supernatant;

the transfection complex is: the packaging plasmids pLP/PsPAX, pLP/VSVG and the plasmid CMV-MCS (PHY-001) vector are mixed and added into an Opti-MEM culture solution, then a transfection reagent Turbofect is added, and the mixture is uniformly mixed and placed for 20 min.

5.2. Packaging lentiviruses carrying CDK4 genes

Packaging lentiviruses carrying the CDK4 gene: inoculating 293T cells into 10% FBS non-resistant DMEM culture solution, culturing at 37 ℃ in a 5% CO2 culture box for 24h, and dropwise adding a transfection compound when the cell density reaches 50%; after culturing for 16h, sucking out the original culture medium, replacing and adding an Advanced DMEM virus packaging solution containing 10% of FBS, 0.01mol/L cholesterol, 0.01mol/L egg yolk lecithin and chemically defined concentrated, continuing culturing for 48h, and collecting cell supernatant to obtain lentivirus supernatant;

5.3 when the fusion degree of the primary human lung idiosyncratic cells reaches 50%, mixing the collected lentivirus supernatant with the DMEM/F12 culture solution according to the ratio of 1: 1, replacing human lung specific channels cells; after 6 hours of transfection, the cells were replaced with new DMEM/F12 medium; and (5) subculturing when the cell fusion degree reaches 80-95%, and identifying the human lung idiosyncratic cells stably transfected with TERT and CDK 4. At 37 deg.C, 5% CO₂After continuous subculturing for more than 50 generations under the condition, a stable human lung specific cell line is obtained.

6. Culturing continuously for 50 generations, and identifying according to morphology and immune markers: observation of the specific structure telopode and immunolabeling were performed to identify the idiosyncratic cells. Positive expression of vimentin, CD34 and PDGFR α was observed under confocal microscopy. After the immune colloidal gold particles are stained, the expression of the specific cells vimentin, CD34 and PDGFR alpha is observed to be positive under an electron microscope.

Compared with the prior art, the invention has the following beneficial effects:

at present, the mouse lung specific channel cell plays an obvious role in a mouse acute lung injury model and an asthma model, and a cell experiment proves that the mouse lung specific channel cell line can regulate the function of an immunocyte. The early-stage research of the invention also finds that the mouse lung idiosyncratic cell line has obvious effects on relieving acute lung injury mouse model lung inflammation, promoting vascular endothelial cell proliferation and inhibiting apoptosis. However, the extraction of primary human lung idiosyncratic cells is very difficult, and further research on human idiosyncratic cells is greatly limited. Meanwhile, the problems of difficult in-vitro amplification, easy differentiation and the like limit basic research on human idiosyncratic cells and possible future clinical research and application.

In vivo, most somatic telomerase expression is tightly regulated, with expression being transient and low. The stable expression of the human TERT gene in the primary cells can effectively activate target cell telomerase and maintain the length of telomeres, so that the cells can obtain the capacity of continuous proliferation. However, in the case of human tercalase cells, reconstitution of telomerase activity is not sufficient to immortalize the cells, and thus the CDK4 gene is transfected at the same time in the present invention, allowing the cells to divide continuously and without transformation of the cell type. The invention solves the bottleneck of further research on human idiosyncratic cells at present, and provides possibility for research on the action mechanism of the idiosyncratic cells and possible clinical application in the future.

The obtained complex cell can be used for basic research on pathogenesis and intervention of acute and chronic diseases, tumors and the like, and can be used for research on communication and interaction between cells and other cell types; it may also be used for clinical treatment in the future.

Preservation information

The culture is preserved in China Center for Type Culture Collection (CCTCC) at 11/02/2021, and the addresses of the China center for type culture Collection are as follows: eight-way Wuhan university 299 in Wuchang area, Wuhan university Collection in Wuhan City, Hubei province, zip code: 430072, the name of the culture is human lung specific cell line hTC-S1011, the preservation number is CCTCC NO: C2021275.

drawings

FIG. 1 is a graph relating to the identification of primary human lung tenocytes;

wherein, A picture is the telopode (@ 200 ×) which is observed and recorded under a microscope and is a characteristic structure of the Rhynchocyte; b is marked by an immunofluorescence method and identified under a laser confocal microscope;

FIG. 2 is an identification diagram of primary human lung Tropical cells by using an immuno-electron microscope;

wherein CD34-20nm is labeled "arp"; vimentin-10nm is marked as "a"; PDGFR alpha-10 nm marker

FIG. 3 is a graph showing the expression identification of TERT gene (Panel A) and CDK4 gene (Panel B) in human lung Terra cells;

FIG. 4 is a graph of proliferation of primary human lung paralogous cells and passaged immortalized human lung paralogous cells;

fig. 5 is the morphology and characteristic structure telopode (× @, 200 ×) under passaged immortalized human lung idiosyncratic cytoscope.

FIG. 6 shows the expression of the relevant immunolabeling markers, vimentin and CD34, in 2 nd, 5 th, 10 th, 20 th, 30 th and 50 th generation cells of immortalized human lung by immunofluorescence and confocal microscopy.

Wherein A is the expression of CD34, vimentin and PDGFR alpha of immortalized human lung specific cell generation 2 cells; panel B shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung paralell generation 5 cells; panel C shows the expression of CD34, vimentin and PDGFR α in immortalized human lung tergital cell passage 10; panel D shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung collateral cells at passage 20; panel E shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung collateral cells at passage 30; panel F shows the expression of CD34, vimentin and PDGFR alpha in the 50 th generation cells of immortalized human lung paralell. Wherein DAPI (blue) marks the nucleus; FITC (green) marker shows expression of vimentin; the keyfluor594 (red) marker shows the expression of CD 34; APC (purple) labeling shows PDGFR α.

FIG. 7 shows the identification of the cells of the idiosyncratic cell line generation 2 (G2), generation 5 (G5), generation 10 (G10), generation 30 (G30) and generation 50 (G50) by immunoelectron microscopyExpression of the relevant immune markers vimentin, CD34, PDGFR α. The sizes of the immune markers and the corresponding immune colloidal gold particles are respectively CD34-20nm and marked as "arp"; vimentin-10nm is marked as "a"; PDGFR alpha-10 nm marker

Detailed Description

In order to make the invention more comprehensible, preferred embodiments are described in detail below with reference to the accompanying drawings:

as shown in FIGS. 1 to 7, the present invention provides a method for constructing a human lung specific cell line, comprising the following steps:

step 1: extracting primary extra-collateral cells by adopting a staged adherence method, and extracting primary human lung extra-collateral cells from waste tissues after operation;

step 2: marking the specific-channel cells by adopting flow cytometry, and adding vimentin, CD34 and PDGFR alpha antibodies into a primary human lung specific-channel cell culture solution;

and step 3: sorting by flow cytometry to obtain CD34⁺PDGFRα⁺vimentin⁺A decomplexated cell;

and 4, step 4: constructing an immortalized human lung idiosyncratic cell line; transfecting primary human lung idiosyncratic cells with lentiviruses carrying a TERT gene and a CDK4 gene; identifying human lung paralytic cells stably transfected with TERT and CDK 4; and continuously subculturing for more than 50 generations to obtain the stable human lung specific cell line.

The invention provides a human lung specific cell line, which is preserved in China Center for Type Culture Collection (CCTCC) at 11/02/2021, the name of the culture is human lung specific cell line hTC-S1011, and the preservation number is CCTCC NO: C2021275.

Examples

The invention provides a method for constructing a human lung idiosyncratic cell line, which comprises the following steps:

1. when primary specific channel cells are extracted, a staged adherence method is adopted: collecting waste tissue after operation, and cutting into 1mm in physiological saline under aseptic condition³The tissue block is placed in 2mg/ml collagenase type II for 30 minutes at 37 ℃, filtered by a sieve with 70 micron aperture, centrifuged for 5 minutes at 1500rpm, the supernatant is discarded, the cell sediment is collected, cultured for 30 minutes in DMEM/F12 culture solution containing 10% FBS, 10-40ng/ml EGF and/or FGF, 2mol/L glutamine and 100mg/ml penicillin/streptomycin, after the fibroblasts are attached to the wall, the supernatant is transferred to another culture dish, the culture solution is changed after 12 hours, and the special-complex cells are observed under a microscope after the fibroblast is cultured for 3-5 days continuously.

2. Flow cytometry labeling of specific cell-specific markers: CD34⁺PDGFRα⁺vimentin⁺Specific collateral cell: culturing primary human lung Tropical cells to 80% cell density, digesting the cells to 80% rounding with trypsin-EDTA digestive juice containing 0.25% trypsin and 0.02% EDTA, sucking the culture solution with a sterile dropper, blowing the cells, filtering with a 75-micrometer-aperture filter screen, centrifuging at 1000rpm for 5min at room temperature; the centrifuged supernatant was discarded, the cells were resuspended in flow staining buffer (1.5% by volume BSA in PBS) and cell viability was calculated; make up the buffer to 100 microliter volume, add 5 microliter each of vimentin, CD34 and PDGFR alpha antibody, incubate for 30 minutes at 4 ℃ in the dark, add 1mL of flow staining buffer,centrifuging at 1000rpm for 5min at 4 deg.C; discard the centrifuged supernatant as 10⁷Cells were supplemented with flow staining buffer at density per mL for flow sorting.

4. Identification based on morphology and immunolabeling: after sorting, observation and identification of specific structure telopode and immunological labeling of specific cells were carried out. Vimentin, CD34 and/or PDGFR α expression should be observed under confocal microscopy. And observing the ultrastructure of the ultramarine cells under an electron microscope. After staining the immune colloidal gold particles, the expression of envelope cells vimentin, CD34 and/or PDGFR alpha was observed under an electron microscope.

5. Constructing an overexpression lentiviral vector;

firstly, designing synthetic primers of TERT and CDK4 respectively, amplifying target fragments respectively, and connecting the TERT or the CDK4 to an enzyme-digested overexpression lentiviral vector through enzyme cleavage sites at two ends of the target fragments; respectively transferring the connecting products into prepared bacterial competent cells, carrying out PCR identification on the grown monoclonal colonies, carrying out sequencing identification on PCR-identified positive colonies, and obtaining the target gene overexpression lentivirus vector successfully constructed by comparing correct clones.

5.1 materials

A. Reagent

Reagent name reagent source

PCR reagent primer (R & F) Biotechnology engineering (Shanghai) Ltd

Taq polymerase NEB

QIAGEN Plasmid Large drawer Kit QIAGEN

BSA Sigma

LB or SOB or SOC Alpha aeser

CaCL2 Sigma

T4 DNA ligase Fermentas

T4 DNA ligase buffer Fermentas

MgSO4 Sigma

Agarose Bio-Rad

DNA ladder Fermentas

Positive clone sequencing Invitrogen

Endonuclease 1Fermentas

Endonuclease 2Fermentas

B. Instrument for measuring the position of a moving object

Instrument name instrument source

Voltage-stabilized electrophoresis apparatus Bio-Rad

Gel imager: marigold instruments manufacturing Ltd

Bacterial shaking table: Shanghai-Heng scientific instruments Co., Ltd

A bacteria incubator: Shanghai-Heng scientific instruments Co., Ltd

A PCR instrument: eppendorf

A high-speed centrifuge: thermo

Disposable plate: experimental apparatus of Haimen of Jiangsu province

1L flask: sichuan cattle

50mL polypropylene tube: corning

A liquid transfer device: gilson

5.2 methods

A. Design and Synthesis of primers

1) The corresponding target gene sequence was found in NCBI based on the gene name.

2) The vector used was determined to be. The carrier name is PHY-801, and the carrier original is EF1A-SV 40-IRES-puro.

3) And finding out the restriction enzyme existing in the target sequence by using sequence analysis software, and determining enzyme cutting sites BamH I and Xba I at two ends of the primer corresponding to the used vector.

4) Primer design software is used for designing a primer, and a determined enzyme cutting site (oligomeric single-stranded DNA sequence 5 ' to 3 ') is added at the 5 ' end.

The sequence of the TERT primer is as follows:

TERT-F:ctaccggactcagatctcgagGCCACC ATGCCGCGCGCTCCCCGCT

TERT-R:TtgttccagacgcgtggatccTCAGTCCAGGATGGTCTTGAAG

the CDK4 primer sequence is:

CDK4-F:ctaccggactcagatctcgagGCCACCATGGCTACCTCTCGATATGAGC

CDK4-R:ttgttccagacgcgtggatccTCACTCCGGATTACCTTCATC

5) the designed primer sequence is sent to the company of Biotechnology engineering (Shanghai) GmbH for synthesis.

B. Double digestion of vectors

1) And (3) culturing the bacterial liquid containing the vector plasmid overnight, and taking 3-5mL of fresh bacterial liquid to extract the plasmid. The specific method refers to QIAGEN plasmid miniprep.

2) Mu.g of fresh plasmid was removed and double digested with the corresponding restriction enzymes. The enzyme digestion system is as follows: support 1. mu.g

green Buffer 3μL

Endonuclease 11.5. mu.L

Endonuclease 21.5. mu.L

ddH2O to make up 30. mu.L

The cleavage was carried out at 37 ℃ for about 3 h.

3) Carrying out agarose gel electrophoresis on the enzyme digestion product, and after the electrophoresis is finished, carrying out gel recovery, wherein the steps are as follows: the gel strip containing the desired fragment was cut under an ultraviolet lamp. The weight of the gel was calculated by subtracting the weight of the empty tube from the balance of the total weight, the volume of the gel was calculated as 100. mu.L/100 mg, and QG buffer was added thereto in an amount of 3 times the volume of the gel, and the gel was completely melted in a 50 ℃ water bath. During which the EP tube was shaken properly to speed up the dissolution of the gel.

4) After the gel is completely melted, isopropanol with the same volume as the gel is added and mixed evenly.

5) The whole amount of the above liquid was transferred to a filter column and centrifuged at 13000rpm for 30 s. The tube was then discarded (once more) and 750. mu.L of PE buffer was added to the column. Centrifuge for 1min. The liquid in the tube was discarded and the tube was again emptied for 2 min. A new 1.5mL EP tube was replaced, and 20. mu.L of ddH2O was added to the column and centrifuged for 1min. To increase recovery, the solubilized DNA may be re-applied to the column and centrifuged for one minute. The column was discarded, the recovered vector fragment, and the concentration was determined.

C. Amplification and enzyme digestion of target fragments:

(1) the synthesized TERT and CDK4 primers were diluted to a final concentration of 10. mu. mol/L, respectively.

(2) PCR amplification was performed using the diluted primers and template, respectively. The system is as follows:

template 1-2. mu.g

Primer F2. mu.L

Primer R2. mu.L

PCR mix 25μL

ddH2O to make up 50. mu.L

The materials are added into a thin-wall tube, mixed evenly and placed into a PCR instrument after point separation, and proper annealing temperature and extension temperature are selected, so that PCR amplification can be started.

(3) After the PCR is finished, agarose gel electrophoresis is respectively carried out, and the target gene is recovered. The method is the same as above.

(4) And (3) carrying out double enzyme digestion on the recovered target genes respectively, wherein the enzyme digestion system is as follows:

PCR recovery product 0.7. mu.g

green Buffer 5μL

Endonuclease 12.5. mu.L

Endonuclease 22.5. mu.L

ddH2O to make up 50. mu.L

The enzyme was cleaved at 37 ℃ for about 5h or overnight.

(5) And (4) performing agarose electrophoresis on the enzyme digestion products respectively and recovering target fragments by the same method.

D. Ligation of overexpression vectors to fragments of interest

(1) Determining the concentration of the recovered carrier and the target fragment, and calculating the ratio of the carrier: the molar ratio of the target fragment to 1:7 was used to calculate the required volume ratio of the vector to the target fragment.

(2) And (3) respectively connecting the TERT and CDK4 overexpression vectors with the target fragment, wherein the connection system is as follows:

160ng of recovery vector

80ng of target fragment

5×CE Entry Buffer 4μL

Exnase entry 2μL

ddH2O to make 20. mu.L

After 30min at 37 ℃ the cells were immediately cooled in an ice-water bath at 5 ℃.

D. Transformation of

(1) After the competent cells were thawed naturally by placing them on ice (4 ℃), 10. mu.L of the ligation product was added to the competent cells and placed on ice (4 ℃) for 30 min.

(2) Then, the mixture was heat-shocked in a water bath at 42 ℃ for 90 seconds. Then quickly placed on ice (4 ℃) for 2-3 min.

(3) Add 500. mu.L of SOC medium without antibiotics and incubate at 37 ℃ for 45min with shaking at 225 rpm.

(4) Centrifuging at 3000rpm for 2min, discarding 900 μ L of supernatant, blowing the bacterial solution at the bottom of the tube, adding into culture plate containing carrier corresponding resistance (ampicillin or kanamycin, etc.), coating with sterilized coater (the temperature of the coater cannot be too high to avoid killing thallus), and culturing in 37 deg.C incubator overnight.

PCR identification

(1) And picking a plurality of single colonies, and carrying out a small amount of shake culture.

(2) And (3) carrying out PCR (polymerase chain reaction) primary identification on the bacterial liquid, wherein the method is the same as the step 3, and only 2-3 mu L of fresh bacterial liquid is replaced by the template.

(3) And selecting two clones from each clone to a sequencing company for sequencing identification on the samples which are preliminarily identified as positive.

6. Constructing an immortalized human lung idiosyncratic cell line:

6.1 packaging of lentiviruses carrying the TERT Gene:

the constructed lentiviral expression vector and packaging plasmid (packaging mix) were used to co-transfect lentiviral packaging cells, coat the virus, collect the virus stock, concentrate by ultrafiltration, and measure titer.

The experimental process comprises the following steps: extracting an overexpression lentivirus vector with high purity and no endotoxin and an auxiliary packaging original vector plasmid thereof, co-transfecting the constructed overexpression lentivirus vector and the auxiliary packaging original vector plasmid thereof into a lentivirus packaging cell by using a transgene reagent, adding an Enhancing buffer after 12h of transfection, replacing a fresh culture medium after 4h, continuously culturing for 48h, collecting cell supernatant rich in lentivirus particles, and concentrating the cell supernatant to obtain a high-titer lentivirus concentrated solution.

A. Experimental Material

1. Cell line

Packaging cells for lentiviruses: 293T, growth medium DMEM (10% FBS). The adherent cells grow and proliferate to form a monolayer of cells after culture.

2. Bacterial strains

Escherichia coli strain DH5 alpha. For amplification of lentiviral vectors and helper packaging vector plasmids.

3. Lentiviral packaging system

The successfully constructed lentivirus recombinant plasmid and the packaging plasmid are extracted by adopting a plasmid extraction kit of Qiagen company. The obtained plasmid DNA is dissolved in sterile TE, and the concentration and the purity of the plasmid DNA are measured by an ultraviolet absorption method, so that the A260/A280 of the quality-improved plasmid DNA is ensured to be between 1.8 and 2.0.

4. Reagent

Name of reagent	Sources of reagents
		Trypan blue	Shanghai Bioengineering Co., Ltd
Fetal bovine serum	GIBCO
		DMSO	sigma
DMEM	GIBCO
		Pancreatin	GIBCO
Polyethylenimine，liner，MW-25000	cat#23966

5. Instrument for measuring the position of a moving object

Name of instrument	Source of instruments
		Fluorescence microscope	AolinBass
CO₂Culture box	Thermo
		Biological safety cabinet	Thermo
Centrifugal ultrafiltration device	MILLIPORE

B. Method of producing a composite material

1. Lentiviral packaging

1) Cell separation disc

One day before transfection, the cells that had grown well were passaged at the appropriate rate into 10cm dishes and were ready for transfection when they had grown to 80% -90%.

2) Fluid exchange before transfection

Cells to be transfected were replaced with fresh medium 1-2h before transfection, 10mL/10cm dish.

3) Transfection

A sterile 1.5mL EP tube was used and the transfection system was as follows:

Opti-MEM	1mL
		Lenti-v	15μg
PA	3μg
		PB	9μg
Polyethylenimine(1mg/mL)	67.5μL

mixing, standing at room temperature for 15-20 min, adding dropwise into culture dish with liquid replaced in advance, and placing in CO₂Culturing in an incubator.

4) Adding an Enhancing buffer

After 12h of transfection, 100 XEnhanning buffer was added dropwise to promote transfection.

5) Liquid changing device

After 18-20h of transfection, the cell culture solution was carefully aspirated and discarded in a waste liquid cup containing a disinfectant solution, and then 15mL of fresh cell culture medium (DMEM containing 2% serum) was added for further culture.

6) Virus collection

And after the liquid is changed for 48 hours, sucking cell supernatant into a 50mL centrifuge tube, centrifuging at 4 ℃ and 4500g for 5min, filtering the supernatant by using a 0.45-micron filter, transferring the filtered liquid into a new centrifuge tube, transferring the filtered liquid into centrifugal filter devices in batches, centrifuging at 4 ℃ and 4500g for 10min, discarding the liquid at the lower layer into a waste liquid cup containing disinfectant, and centrifuging at 4 ℃ and 4500g for 20min for the last time, wherein the liquid at the upper layer of the filter is the virus concentrated liquid.

7) Virus packaging and preservation

The virus was aliquoted at 50. mu.L and stored at-80 ℃.

2. Titre determination

1) RT-PCR analysis of integrated copy number

In the virus detection, 0.1. mu.L of plasmid standard and genomic DNA of the sample to be detected were taken, and 1 well was left to be added with sterile water as a no-template control. Each sample was repeated 1 time. Genome detection 0.1. mu.L of genome standard and genome DNA of a sample to be detected were taken, and 1 well was left to add sterile water as a no-template control (no-template). Each sample was repeated 1 time. The RT-PCR cycling conditions were set as: 5min at 95 ℃ followed by 40 cycles of 15s at 95 ℃ and 1min at 60 ℃.

2) Titre determination

The number of integrated lentiviral vector copies in the DNA sample determined is calibrated by the number of genomes to obtain the number of integrated viral copies per genome. The titer (integration units per mL, IU mL-1) was calculated as follows: IU mL-1 ═ C × N × D × 1000)/V. Wherein: c-the average number of integrated viral copies per genome; n-the number of cells at infection; d-dilution of viral vector-10; v ═ number of volumes of added diluted virus (0.5 μ L, 5 μ L, 50 μ L and 100 μ L). Titer span of 10⁷-10⁹。

6.2 construction of overexpression Stable transformants:

1. the identified purified primary human lung idiosyncratic cells were divided into 3 groups: primary human lung specific channel cell group (cell untransfected), NC group (empty vector Lenti transfected control group), and human lung specific channel cell line group (recombinant lentivirus expression vector TERT and CDK4 transfected group). Target cells were seeded in 6-well plates at the appropriate ratio (approximately 50% degree of polymerization). After 24h, before infection, stock solutions of the virus with TERT and CDK4 were removed from a freezer at-80 deg.CAfter the cell is taken out, the cell is melted in ice bath, the virus stock solution is diluted by fresh culture medium containing 8 mu g/mL Polybrene of infection enhancer, the old culture medium in a 6-well plate is removed by suction, the diluted solution containing the slow virus is added into the target cell, and the solution is changed after 6 hours. The lentiviral vector was resistant to puromycin, and 2. mu.g/mL puromycin, 37 ℃ C., 5% CO was added to the cells₂And culturing for 24h conventionally to screen stable transformants. DMEM is replaced to continue culture, and when the cell polymerization degree is about 80% -90%, the cell polymerization degree is transferred to a culture bottle. Fifth day, infection efficiency test: after stable transformants were harvested, the infection efficiency was verified by RT-qPCR.

2. Amplification and validation of fragments of interest

(1) RNA was extracted from each cell group using QIAGEN RNA extraction kit according to the kit protocol. Firstly, using OLIGO hexamer as reverse transcription primer, extracting total RNA in each group of cells as template, and reverse transcribing cDNA under the catalysis of reverse transcriptase. The system is as follows: RNA template 500ng,5 Xbuffer 2. mu.L, primescript RT Enzymemix I0.5. mu.L, 10. mu. mol/L50. mu.M OLIGO hexamer 0.5. mu.L, 100. mu.M Random 6mers 0.5. mu.L, DEPC water make up 10. mu.L. 15min at 37 ℃.

(2) PCR amplification is carried out by taking the synthesized cDNA as a template and using upstream and downstream primers of TERT or CDK4 genes. And (3) observing the electrophoresis of the amplified products, wherein the recombinant lentivirus expression vector TERT or CDK4 transfection group shows a strip, the strip is preliminarily determined to be the amplification product of the corresponding gene, and the other two groups do not show the strip.

The sequence of the TERT primer is as follows:

TERT-F:ctaccggactcagatctcgagGCCACC ATGCCGCGCGCTCCCCGCT

TERT-R:TtgttccagacgcgtggatccTCAGTCCAGGATGGTCTTGAAG

the CDK4 primer sequence is:

CDK4-F:ctaccggactcagatctcgagGCCACCATGGCTACCTCTCGATATGAGC

CDK4-R:ttgttccagacgcgtggatccTCACTCCGGATTACCTTCATC

and (3) when the fusion degree of the primary human lung idiosyncratic cells reaches 50%, mixing the collected lentivirus supernatant with a DMEM/F12 culture solution according to the ratio of 1: 1, replacing human lung specific channels cells; after 6 hours of transfection, the cells were replaced with new DMEM/F12 medium; when the degree of cell fusion reachesSubculturing at 80-95%. At 37 deg.C, 5% CO₂After serial subculturing for more than 50 generations under the conditions, human lung paralogous cells stably transfected with TERT and CDK4 were obtained.

7. Continuously culturing for more than 50 generations, and identifying according to characteristic morphology and expression of immune markers: the telopode structure specific to the terluo cells was observed under a microscope and photographed. And (3) carrying out immunolabeling labeling, identifying the specific collateral cells by fluorescence, and observing that the expression of vimentin, CD34 and/or PDGFR alpha is positive under a laser confocal microscope. After staining the immune colloidal gold particles, the expression of the specific network cells vimentin, CD34 and/or PDGFR alpha is observed to be positive under an electron microscope.

The experimental results are as follows:

1. identification of primary human lung idiosyncratic cells:

as shown in fig. 1, telopode (≈ 200 ×) characteristic structure of the tyruocyte was observed and recorded under a microscope; marking by an immunofluorescence method, and identifying under a laser confocal microscope. The results showed expression of the collateral cell associated immune markers CD34, vimentin and PDGFR α, with the keyfluor594 (red) marker showing expression of CD34, the FITC (green) marker showing expression of vimentin, and the APC (purple) marker showing PDGFR α, DAPI (blue) marking the nucleus.

As shown in fig. 2, immunoelectron microscopy identified the expression of the envelope-associated immune markers vimentin, CD34 and PDGFR α. The expression of the immune markers vimentin, CD34 and PDGFR alpha related to the specific cells can be seen under an immunoelectron microscope. The sizes of the immune marker and the corresponding immune colloidal gold particles are respectively CD34-20 nm; vimentin-10 nm; PDGFR alpha-10 nm.

2. Identification of transfected TERT Gene and CDK4 Gene

2.1 sequencing of the plasmid containing the TERT gene resulted in the following:

gtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgactctactagaggatcgctagcgctaccggactcagatctcgaggccaccATGCCGCGCGCTCCCCGCTGCCGAGCCGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAGGTGCTGCCGCTGGCCACGTTCGTGCGGCGCCTGGGGCCCCAGGGCTGGCGGCTGGTGCAGCGCGGGGACCCGGCGGCTTTCCGCGCGCTGGTGGCCCAGTGCCTGGTGTGCGTGCCCTGGGACGCACGGCCGCCCCCCGCCGCCCCCTCCTTCCGCCAGGTGTCCTGCCTGAAGGAGCTGGTGGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCGGCGCGAAGAACGTGCTGGCCTTCGGCTTCGCGCTGCTGGACGGGGCCCGCGGGGGCCCCCCCGAGGCCTTCACCACCAGCGTGCGCAGCTACCTGCCCAACACGGTGACCGACGCACTGCGGGGGAGCGGGGCGTGGGGGCTGCTGCTGCGCCGCGTGGGCGACGACGTGCTGGTTCACCTGCTGGCACGCTGCGCGCTCTTTGTGCTGGTGGCTCCCAGCTGCGCCTACCAGGTGTGCGGGCCGCCGCTGTACCAGCTCGGCGCTGCCACTCAGGCCCGGCCCCCGCCACACGCTAGTGGACCCCGAAGGCGTCTGGGATGCGAACGGGCCTGGAACCATAGCGTCAGGGAGGCCGGGGTCCCCCTGGGCCTGCCAGCCCCGGGTGCGAGGAGGCGCGGGGGCAGTGCCAGCCGAAGTCTGCCGTTGCCCAAGAGGCCCAGGCGTGGCGCTGCCCCTGAGCCGGAGCGGACGCCCGTTGGGCAGGGGTCCTGGGCCCACCCGGGCAGGACGCGTGGACCGAGTGACCGTGGTTTCTGTGTGGTGTCACCTGCCAGACCCGCCGAAGAAGCCACCTCTTTGGAGGGTGCGCTCTCTGGCACGCGCCACTCCCACCCATCCGTGGGCCGCCAGCACCACGCGGGCCCCCCATCCACATCGCGGCCACCACGTCCCTGGGACACGCCTTGTCCCCCGGTGTACGCCGAGACCAAGCACTTCCTCTACTCCTCAGGCGACAAGGAGCAGCTGCGGCCCTCCTTCCTACTCAGCTCTCTGAGGCCCAGCCTGACTGGCGCTCGGAGGCTCGTGGAGACCATCTTTCTGGGTTCCAGGCCCTGGATGCCAGGGACTCCCCGCAGGTTGCCCCGCCTGCCCCAGCGCTACTGGCAAATGCGGCCCCTGTTTCTGGAGCTGCTTGGGAACCACGCGCAGTGCCCCTACGGGGTGCTCCTCAAGACGCACTGCCCGCTGCGAGCTGCGGTCACCCCAGCAGCCGGTGTCTGTGCCCGGGAGAAGCCCCAGGGCTCTGTGGCGGCCCCCGAGGAGGAGGACACAGACCCCCGTCGCCTGGTGCAGCTGCTCCGCCAGCACAGCAGCCCCTGGCAGGTGTACGGCTTCGTGCGGGCCTGCCTGCGCCGGCTGGTGCCCCCAGGCCTCTGGGGCTCCAGGCACAACGAACGCCGCTTCCTCAGGAACACCAAGAAGTTCATCTCCCTGGGGAAGCATGCCAAGCTCTCGCTGCAGGAGCTGACGTGGAAGATGAGCGTGCGGGACTGCGCTTGGCTGCGCAGGAGCCCAGGGGTTGGCTGTGTTCCGGCCGCAGAGCACCGTCTGCGTGAGGAGATCCTGGCCAAGTTCCTGCACTGGCTGATGAGTGTGTACGTCGTCGAGCTGCTCAGGTCTTTCTTTTATGTCACGGAGACCACGTTTCAAAAGAACAGGCTCTTTTTCTACCGGAAGAGTGTCTGGAGCAAGTTGCAAAGCATTGGAATCAGACAGCACTTGAAGAGGGTGCAGCTGCGGGAGCTGTCGGAAGCAGAGGTCAGGCAGCATCGGGAAGCCAGGCCTGCCCTGCTGACGTCCAGACTCCGCTTCATCCCCAAGCCTGACGGGCTGCGGCCGATTGTGAACATGGACTACGTCGTGGGAGCCAGAACGTTCCGCAGAGAAAAGAGGGCCGAGCGTCTCACCTCGAGGGTGAAGGCACTGTTCAGCGTGCTCAACTACGAGCGGGCGCGGCGCCCCGGCCTCCTGGGCGCCTCTGTGCTGGGCCTGGACGATATCCACAGGGCCTGGCGCACCTTCGTGCTGCGTGTGCGGGCCCAGGACCCGCCGCCTGAGCTGTACTTTGTCAAGGTGGATGTGACGGGCGCGTACGACACCATCCCCCAGGACAGGCTCACGGAGGTCATCGCCAGCATCATCAAACCCCAGAACACGTACTGCGTGCGTCGGTATGCCGTGGTCCAGAAGGCCGCCCATGGGCACGTCCGCAAGGCCTTCAAGAGCCACGTCTCTACCTTGACAGACCTCCAGCCGTACATGCGACAGTTCGTGGCTCACCTGCAGGAGACCAGCCCGCTGAGGGATGCCGTCGTCATCGAGCAGAGCTCCTCCCTGAATGAGGCCAGCAGTGGCCTCTTCGACGTCTTCCTACGCTTCATGTGCCACCACGCCGTGCGCATCAGGGGCAAGTCCTACGTCCAGTGCCAGGGGATCCCGCAGGGCTCCATCCTCTCCACGCTGCTCTGCAGCCTGTGCTACGGCGACATGGAGAACAAGCTGTTTGCGGGGATTCGGCGGGACGGGCTGCTCCTGCGTTTGGTGGATGATTTCTTGTTGGTGACACCTCACCTCACCCACGCGAAAACCTTCCTCAGGACCCTGGTCCGAGGTGTCCCTGAGTATGGCTGCGTGGTGAACTTGCGGAAGACAGTGGTGAACTTCCCTGTAGAAGACGAGGCCCTGGGTGGCACGGCTTTTGTTCAGATGCCGGCCCACGGCCTATTCCCCTGGTGCGGCCTGCTGCTGGATACCCGGACCCTGGAGGTGCAGAGCGACTACTCCAGCTATGCCCGGACCTCCATCAGAGCCAGTCTCACCTTCAACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGCTGAAGTGTCACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGACGGTGTGCACCAACATCTACAAGATCCTCCTGCTGCAGGCGTACAGGTTTCACGCATGTGTGCTGCAGCTCCCATTTCATCAGCAAGTTTGGAAGAACCCCACATTTTTCCTGCGCGTCATCTCTGACACGGCCTCCCTCTGCTACTCCATCCTGAAAGCCAAGAACGCAGGGATGTCGCTGGGGGCCAAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCAAGCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGCTCCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACTGAggatccacgcgtctggaacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccc

2.2 sequencing of plasmids containing the CDK4 gene resulted in the following:

cctggagacgccatccacgctgttttgacctccatagaagacaccgactctactagaggatcgctagcgctaccggactcagatctcgaggccaccATGGCTGCCACTCGATATGAACCCGTGGCTGAAATTGGTGTCGGTGCCTATGGGACGGTGTACAAAGCCCGAGATCCCCACAGTGGCCACTTTGTGGCCCTCAAGAGTGTGAGAGTTCCTAATGGAGGAGCAGCTGGAGGGGGCCTTCCCGTCAGCACAGTTCGTGAGGTGGCCTTGTTAAGGAGGCTGGAGGCCTTTGAACATCCCAATGTTGTACGGCTGATGGATGTCTGTGCTACTTCCCGAACTGATCGGGACATCAAGGTCACCCTAGTGTTTGAGCATATAGACCAGGACCTGAGGACATACCTGGACAAAGCACCTCCACCGGGCCTGCCGGTTGAGACCATTAAGGATCTAATGCGTCAGTTTCTAAGCGGCCTGGATTTTCTTCATGCAAACTGCATTGTTCACCGGGACCTGAAGCCAGAGAACATTCTAGTGACAAGTAATGGGACCGTCAAGCTGGCTGACTTTGGCCTAGCTAGAATCTACAGCTACCAGATGGCCCTCACGCCTGTGGTGGTTACGCTCTGGTACCGAGCTCCTGAAGTTCTTCTGCAGTCTACATACGCAACACCCGTGGACATGTGGAGCGTTGGCTGTATCTTTGCAGAGATGTTCCGTCGGAAGCCTCTCTTCTGTGGAAACTCTGAAGCCGACCAGTTGGGGAAAATCTTTGATCTCATTGGATTGCCTCCAGAAGACGACTGGCCTCGAGAGGTATCTCTACCTCGAGGAGCCTTTGCCCCCAGAGGGCCTCGGCCAGTGCAGTCAGTGGTGCCAGAGATGGAGGAGTCTGGAGCGCAGCTGCTACTGGAAATGCTGACCTTTAACCCACATAAGCGAATCTCTGCCTTCCGAGCCCTGCAGCACTCCTACCTGCACAAGGAGGAAAGCGACGCAGAGTGAggatccacgcgtctggaacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgt

as shown in FIG. 3, the expression of TERT gene (panel A) and CDK4 gene (panel B) in human lung reticulocytes was identified by agarose gel electrophoresis after transfection of TERT gene and CDK4 gene.

3. Identification of immortalized human lung terglume cells with stable proliferative capacity (growth curve assay):

untransfected primary human lung paralog cells and passaged immortalized human lung paralog cells (passage 2, passage 5, passage 10, passage 20, passage 30, passage 40 and passage 50) were seeded in 96-well plates (n ═ 6) at a cell density of 1X 103/well, and at 37 ℃ with 5% CO₂Culturing for 0h, 6h, 12h, 18h, 24h, 30h, 36h, 42h, 48h, 54h, 60h, 66h and 72h, adding 10 μ L cell Counting Kit-8(CCK8) solution into each well, returning the culture plate to 37 deg.C, and 5% CO₂Incubate in incubator for 20min, use microplate reader to measure absorbance at 450 nm. Comparing the growth curves of passaged immortalized human lung paralell and untransfected primary human lung paralell, the results showed that transfected primary human lung paralell showed almost no proliferation, while passaged immortalized human lung paralell showed stable proliferation within 72h (see fig. 4).

4. Identification of the stability of the human lung specific cell line with continuous passage:

4.1 Observation of immortalized human lung specific channel cell characteristic structures telopode at passage 2 (G2), passage 5 (G5), passage 10 (G10), passage 15 (G15), passage 20 (G20), passage 25 (G25), passage 30 (G30), passage 35 (G35), passage 40 (G40), passage 45 (G45), passage 50 (G50) and passage 55 (G55) was performed by a light microscope, and photographed and recorded. As shown in fig. 5, the immortalized human lung idiosyncratic cellular structures telopode (× 200) at passage 2, passage 5, passage 10, passage 15, passage 20, passage 25, passage 30, passage 35, passage 40, passage 45, passage 50 and passage 55, respectively.

4.2 immunofluorescence method for labeling immortalized human lung special network cells in 2 nd, 5 th, 10 th, 20 th, 30 th and 50 th generation cells related immune marker vimentin and CD34 expression, and in laser confocal microscope observation and photograph (as shown in figure 6). Panel A shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung paralell generation 2 cells; panel B shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung paralell generation 5 cells; panel C shows the expression of CD34, vimentin and PDGFR α in immortalized human lung tergital cell passage 10; panel D shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung collateral cells at passage 20; panel E shows the expression of CD34, vimentin and PDGFR alpha in immortalized human lung collateral cells at passage 30; panel F shows the expression of CD34, vimentin and PDGFR alpha in the 50 th generation cells of immortalized human lung paralell. Wherein DAPI (blue) marks the nucleus; FITC (green) marker shows expression of vimentin; the keyfluor594 (red) marker shows the expression of CD 34; APC (purple) labeling shows PDGFR α.

4.3 identifying by immunoelectron microscopy the expression of the relevant biomarkers vimentin, CD34, PDGFR α and ckit in cells of the idiosyncratic cell line passage 2 (G2), passage 5 (G5), passage 10 (G10), passage 30 (G30) and passage 50 (G50). As shown in fig. 7, the immune markers and the corresponding immune colloidal gold particles were CD34-20nm in size, respectively; vimentin-10 nm; PDGFR alpha-10 nm.

The application of the human lung specific cell line of the invention is as follows:

1. can be used for basic research: can be used for basic research of pathogenesis and intervention of acute and chronic diseases, tumors and the like, and can be used for self-studyOr the study of cell-to-cell communication and interactions of other cell types, etc. The cell experiment suggests a cell concentration of 10⁶-10⁷Perml, the recommended inoculation density is 70-90%, and the digestion and culture methods are the same as those described above. Recommended concentration for animal experiments is 10⁴-10⁶And/ml, intravenous injection or local administration, and filtering with a 300-mesh filter screen of 200 meshes before administration.

2. May be used for clinical treatment in the future. According to the animal experiments of the existing mouse lung Terra-luvifolia cells, the treatment range of the human Terra-luvifolia cells is presumed to possibly comprise prevention and early treatment of acute lung injury, early treatment of acute myocardial infarction, treatment of chronic refractory wound surfaces and the like. The expanded treatment range may be the prevention and treatment of acute and chronic diseases. Other treatment ranges refer to stem cells, and the stem cells can be used for supporting treatment of malignant tumor radiotherapy and chemotherapy, adjuvant treatment of diabetes and leukemia, treatment of Parkinson's disease, senile dementia, sub-health state and the like.

While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.

Claims

1. A human lung terluo cell line, characterized by: is an immortalized idiosyncratic cell line; the cell strain is preserved in China Center for Type Culture Collection (CCTCC) at 11/02/2021, the name of the culture is hTC-S1011, and the preservation number is CCTCC NO: C2021275.

2. use of a human lung specific cell line according to claim 1 for the construction of a disease model.

3. Use of a human lung specific cell line according to claim 1 in the construction of a model for studying cell-cell communication and interaction.

4. The use of the human lung specific cell line of claim 1 in the construction of models for clinical drug screening and drug therapy mechanism research.

5. Use of a human lung decomplexation cell line according to claim 1 for the preparation of a medicament for the treatment and/or prevention of acute lung injury.

6. Use of a human lung tercala cell line according to claim 1 for the preparation of a medicament for the early treatment of acute myocardial infarction.

7. Use of a human lung terglu cell line according to claim 1 for the preparation of a medicament for the treatment of chronic refractory wounds.

8. Use of a human lung tercala cell line according to claim 1 for the preparation of a medicament for cell therapy.